StemCells, Inc of Newark, California, sponsor of innovative stem cell therapies for neurodegenerative disorders, have announced the successful transplantation of HuCNS-SC (purified human neural stem cells) into the first five patients in the final cohort of the company’s 16-patient phase I/II trial for geographic atrophy of age related macular degeneration (GA-AMD). Commenting on the milestone, Stephen Huhn, VP for CNS Clinical Research at StemCells, Inc stated, “we are very pleased with the rate of progress being made towards our goal of completing enrollment in this study by the end of this quarter. We look forward to releasing the first interim results from this study next month and are planning to initiate a controlled Phase II proof-of-concept study later this year.”